Pink SheetWith 10 novel applications with August user fee goal dates remaining under review, the US Food and Drug Administration could make some headway toward FDA Commissioner Martin Makary’s ambitious 2025 ap
Pink SheetUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
ScripUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
ScripAtai Life Sciences said it will focus entirely on the combined psychedelic therapy portfolio it holds under a pending merger with Beckley Psytech in the aftermath of Recognify Life Sciences reporting